Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea - patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed's lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep. Based in Cambridge, Mass., the company is developing a portfolio of novel pharmacologic therapies for sleep apnea and related disorders.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/03/23 | $79,750,000 | Series C |
Alpha Wave Ventures Columbia-Seligman Investments Sectoral Asset Management Tao Capital Partners | undisclosed |
